- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00009243
Histoire naturelle de l'AVC : cause et développement
Évaluation, pathogenèse et traitement des patients atteints ou à risque de maladie cérébrovasculaire (un protocole d'histoire naturelle/pathogenèse de la maladie)
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.
Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.
The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:
- Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.
- Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.
- Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.
- Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.
- Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.
- Echocardiogram-sound waves are used to image the heart and evaluate heart function.
Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time
Aperçu de l'étude
Statut
Description détaillée
Study Description:
This is a natural history/disease pathogenesis protocol for evaluation of patients with or at risk of acute stroke, transient ischemic attack (TIA), or other disturbances of cerebrovascular circulation. The purpose of this protocol is to generate natural history data to serve as the basis for future hypothesis-driven protocols as well as to contribute to the clinical and physiological understanding of cerebrovascular disease through the description of disease manifestation and the relationship among clinical, hematologic, and radiologic variables, as well as identifying potential subjects for future studies on stroke and other cerebrovascular diseases.
Objectives:
- To establish a registry of subjects with cerebrovascular disease including clinical, laboratory, and radiological variables associated with hemorrhagic and ischemic stroke, TIA, and other disturbances of cerebrovascular circulation.
- To characterize the natural history of acute stroke, TIA, and other disturbances of cerebrovascular circulation on these variables.
- To evaluate the relationship among these variables by exploratory analyses and to generate hypotheses for future testing.
- To identify potential subjects for research studies on stroke and other cerebrovascular diseases.
Endpoints:
A primary purpose of this observational protocol is to discover and study new imaging biomarkers that are i) relevant to the acute presentation and severity, ii) predictive of clinical outcome, and iii) are useful for stratifying the biological response as reflected in blood-biomarker and gene expression studies. As such, the primary outcome is the results from the imaging studies.
Primary Outcome Measures
Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult such as:
- Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )[1]
- Presence of a lesion on diffusion, perfusion, and mismatch between the two
- Evidence of a vascular occlusion on MR angiography
- Evidence of a thrombus or hemorrhage on T2* GRE imaging
- Blood-brain barrier disruption as evidence by HARM [2]
- The evolution of these markers with time and treatment
Secondary Outcome Measures
- Stroke severity as measured by NIHSS as a function of time since index event.
- Clinical outcome measured using modified Rankin Scale and Barthel Index
- Gene expression profiles and biomarker levels obtained from blood samples.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nicole L Peterkin
- Numéro de téléphone: (301) 435-2395
- E-mail: nicole.peterkin@nih.gov
Sauvegarde des contacts de l'étude
- Nom: Lawrence L Latour, Ph.D.
- Numéro de téléphone: (301) 435-2395
- E-mail: latourl@ninds.nih.gov
Lieux d'étude
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- Medstar Washington Hospital Center
-
Contact:
- Lawrence Latour, Ph.D.
- Numéro de téléphone: 301-435-2395
- E-mail: latourl@ninds.nih.gov
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Recrutement
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Numéro de téléphone: TTY dial 711 800-411-1222
- E-mail: ccopr@nih.gov
-
Bethesda, Maryland, États-Unis, 20814
- Recrutement
- Suburban Hospital - Johns Hopkins Medicine
-
Contact:
- Lawrence Latour, Ph.D.
- Numéro de téléphone: 301-435-2395
- E-mail: latourl@ninds.nih.gov
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Subjects are recruited from the collaborative stroke programs between NINDS and affiliated hospitals (Suburban Hospital and MedStar Washington Hospital Center) and will be followed for the duration of their hospitalization. Select subjects will then be seen for follow up for up to one year.
La description
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Aged >=18
- Presented to participating study site (ED, ICU, or inpatient unit) with or at risk of acute stroke, TIA, or other disturbances of cerebrovascular circulation
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Subjects with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. The contraindications include subjects with the following devices or conditions:
- Central nervous system aneurysm clips
- Implanted neural stimulator
- Implanted cardiac pacemaker or defibrillator
- Cochlear implant
- Ocular foreign body (e.g. metal shavings)
- Insulin pump
- Metal shrapnel or bullet
- Any implanted device that is incompatible with MRI
Subjects with a condition precluding entry in the scanner (e.g. morbid obesity, Claustrophobia, etc.) will not be included in the MRI portion of this study.
-
Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Patients
Patients with acute stroke symptoms |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult
Délai: Post-acute, 24 hours, 5 days/discharge, 30 days
|
Neuroimaging abnormalities, such as:-Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )-Presence of a lesion on diffusion, perfusion, and mismatch between the two-Evidence of a vascular occlusion on MR angiography-Evidence of a thrombus or hemorrhage on T2* GRE imaging-Blood-brain barrier disruption as evidence by "HARM"-The evolution of these markers with time and treatment |
Post-acute, 24 hours, 5 days/discharge, 30 days
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Gravité de l'AVC mesurée par le NIHSS en fonction du temps écoulé depuis l'événement index
Délai: Post-aigu, 24 heures, 5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
Post-aigu, 24 heures, 5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
|
Résultat clinique mesuré à l'aide de l'échelle de Rankin modifiée et de l'indice de Barthel
Délai: 5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
|
Profils d'expression génique et niveaux de biomarqueurs obtenus à partir d'échantillons sanguins
Délai: Post-aigu, 24 heures, 5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
Post-aigu, 24 heures, 5 jours/sortie, 30 jours, 3 mois, 6 mois, 12 mois
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Lawrence L Latour, Ph.D., National Institute of Neurological Disorders and Stroke (NINDS)
Publications et liens utiles
Publications générales
- Cho YE, Lee H, Bae HR, Kim H, Yun S, Vorn R, Cashion A, Rucker MJ, Afzal M, Latour L, Gill J. Circulating immune cell landscape in patients who had mild ischaemic stroke. Stroke Vasc Neurol. 2022 Aug;7(4):319-327. doi: 10.1136/svn-2021-001224. Epub 2022 Mar 9.
- Luby M, Hsia AW, Nadareishvili Z, Cullison K, Pednekar N, Adil MM, Latour LL. Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients. Stroke. 2019 Aug;50(8):2241-2244. doi: 10.1161/STROKEAHA.119.025914. Epub 2019 Jun 26.
- Hsia AW, Luby M, Cullison K, Burton S, Armonda R, Liu AH, Leigh R, Nadareishvili Z, Benson RT, Lynch JK, Latour LL. Rapid Apparent Diffusion Coefficient Evolution After Early Revascularization. Stroke. 2019 Aug;50(8):2086-2092. doi: 10.1161/STROKEAHA.119.025784. Epub 2019 Jun 26.
- Lomahan CA, Luby M, Kalarakis G, Hsia AW, Lynch JK, Nathani KP, Somani S, Thomas LC, Arnberg-Sandor F, Latour LL. Hyperemia detection on arterial spin labeling is associated with final infarct volume in stroke post-endovascular therapy. J Stroke Cerebrovasc Dis. 2025 Aug;34(8):108358. doi: 10.1016/j.jstrokecerebrovasdis.2025.108358. Epub 2025 May 26.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 010007
- 01-N-0007
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual Participant Data that underlie the results reported in the publication, after deidentification.
Délai de partage IPD
Beginning 3 months and ending 5 years after article publication.
Critères d'accès au partage IPD
IPD will be shared with researchers who provide a methodologically sound proposal . Proposals should be sent to the corresponding author of the publication.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .